PT  - JOURNAL ARTICLE
AU  - Michael Carling
AU  - Avinash Aujayeb
TI  - VTE in COVID-19 inpatients not receiving higher level care
AID  - 10.1183/13993003.congress-2021.PA495
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA495
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA495.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA495.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: Covid-19 causes a prothrombotic state. Deep venous thromboembolism (VTE) is noted in 1.1% in non-ICU (intensive care unit) and up to 69% in ICU patients, with some advocating VTE scanning for all. Patients requiring high level care (HLC) and/or Fi02 ≥ 40% currently receive enhanced thromboprophylaxis (ET) locally with twice daily tinzaparin. We sought to identify VTE incidence in those not receiving HLC.Methods: Covid-19 inpatients not receiving HLC from Northumbria Healthcare NHS Trust (NHCT) between 1st Mar 2020 to 27th Apr 2020 were analysed. Descriptive statistical methodology was applied.Results: 348 patients were identified, and 15 developed VTE (4%) [5 pulmonary emboli/10 limb venous emboli): mean age 68.7 (range 29-90), 9 male, 6 female All had positive PCR swabs, 3 patients received ET initially (Fi02 ≥ 40%), the rest standard once daily tinzaparin dose. Common presenting symptoms were cough (10), dyspnoea (10), fever (8). Mean clinical frailty score was 4 (1-7) and mean BMI was 26.1 (20-44).  Co-morbidities included heart failure (1), asthma (1), bronchiectasis (1), hypertension (2), diabetes (2), atrial fibrillation (1), kidney disease (1), and active cancer (3). 1 death occurred during the inpatient stay due to active progressive cancer. D dimer levels were only measured in 4 patients, and were all raised. Well’s scores were high in all patients.Conclusions: In Covid-19 patients not receiving high level care, VTE risk is not insignificant. As per known data, D dimers are not useful and clinical risk assessment is useful. Patients tend to be co-morbid, male, with an above average BMI and a lower than average frailty score.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA495.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).